Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Tumor Biology
Published in: Tumor Biology 12/2014

01-12-2014 | Research Article

Genetic association between cyclin D1 polymorphism and breast cancer susceptibility

Authors: XiaoRui Li, XiaoQing Huo, WeiWei Li, QingHui Yang, Ying Wang, XiaoChun Kang

Published in: Tumor Biology | Issue 12/2014

Login to get access

Abstract

Cyclin D1 polymorphism has been reported to be associated with risk of breast cancer, but the published studies have yielded controversial results. This study was undertaken to derive a precise risk estimate for the cyclin D1 polymorphism associated with breast cancer risk. We performed a search of EMBASE, PubMed, and Web of Science. In total, data from 18 publications were pooled and the association was assessed by odds ratios (ORs) with 95 % confidence intervals (CIs). This analysis showed that there was no obvious association between the cyclin D1 polymorphism and breast cancer risk in any of the analyzed genetic model. We found the same negative association in stratified analyses by ethnicity, source of controls, and sample size. Our meta-analysis provides an estimate that the presence of cyclin D1 polymorphism may not confer susceptibility to breast cancer.
Literature
1.
Ormandy CJ et al. Cyclin D1, EMS1 and 11q13 amplification in breast cancer. Breast Cancer Res Treat. 2003;78(3):323–35.PubMedCrossRef
2.
Motokura T et al. A novel cyclin encoded by a bcl1-linked candidate oncogene. Nature. 1991;350(6318):512–5.PubMedCrossRef
3.
Knudsen KE et al. Cyclin D1: polymorphism, aberrant splicing and cancer risk. Oncogene. 2006;25(11):1620–8.PubMedCrossRef
4.
Reed SI. The role of p34 kinases in the G1 to S-phase transition. Annu Rev Cell Biol. 1992;8:529–61.PubMedCrossRef
5.
6.
7.
Sutherland RL, Musgrove EA. Cyclin D1 and mammary carcinoma: new insights from transgenic mouse models. Breast Cancer Res. 2002;4(1):14–7.PubMedCrossRef
8.
Ewen ME et al. Functional interactions of the retinoblastoma protein with mammalian D-type cyclins. Cell. 1993;73(3):487–97.PubMedCrossRef
9.
Bala S, Peltomaki P. Cyclin D1 as a genetic modifier in hereditary nonpolyposis colorectal cancer. Cancer Res. 2001;61(16):6042–5.PubMed
10.
Casson AG et al. Cyclin D1 polymorphism (G870A) and risk for esophageal adenocarcinoma. Cancer. 2005;104(4):730–9.PubMedCrossRef
11.
Hou X et al. Cyclin D1 gene polymorphism and susceptibility to childhood acute lymphoblastic leukemia in a Chinese population. Int J Hematol. 2005;82(3):206–9.PubMedCrossRef
12.
Hung RJ et al. Sequence variants in cell cycle control pathway, X-ray exposure, and lung cancer risk: a multicenter case-control study in Central Europe. Cancer Res. 2006;66(16):8280–6.PubMedCrossRef
13.
Zheng Y et al. Cyclin D1 polymorphism and risk for squamous cell carcinoma of the head and neck: a case-control study. Carcinogenesis. 2001;22(8):1195–9.PubMedCrossRef
14.
Grieu F et al. Lack of association between CCND1 G870A polymorphism and the risk of breast and colorectal cancers. Anticancer Res. 2003;23(5b):4257–9.PubMed
15.
Ceschi M et al. The effect of cyclin D1 (CCND1) G870A-polymorphism on breast cancer risk is modified by oxidative stress among Chinese women in Singapore. Carcinogenesis. 2005;26(8):1457–64.PubMedCrossRef
16.
Shu XO et al. Association of cyclin D1 genotype with breast cancer risk and survival. Cancer Epidemiol Biomarkers Prev. 2005;14(1):91–7.PubMed
17.
18.
Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959;22(4):719–48.PubMed
19.
20.
Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21(11):1539–58.PubMedCrossRef
21.
22.
Abramson VG et al. Cyclin D1b in human breast carcinoma and coexpression with cyclin D1a is associated with poor outcome. Anticancer Res. 2010;30(4):1279–85.PubMedPubMedCentral
23.
Labonte MJ et al. The Cyclin D1 (CCND1) A870G polymorphism predicts clinical outcome to lapatinib and capecitabine in HER2-positive metastatic breast cancer. Ann Oncol. 2012;23(6):1455–64.PubMedCrossRef
24.
25.
Al DA, Qureshi S, Al Saleh KA, Al Qahtani FH, Aleem A, AlSaif A, et al. Studies on the methods of diagnosis and biomarkersused in early detection of breast cancer in the Kingdom of Saudi Arabia: an overview. World J Med Sci. 2013;8(1):36–47.
26.
Krippl P et al. The 870G > A polymorphism of the cyclin D1 gene is not associated with breast cancer. Breast Cancer Res Treat. 2003;82(3):165–8.PubMedCrossRef
27.
Forsti A et al. Single nucleotide polymorphisms in breast cancer. Oncol Rep. 2004;11(4):917–22.PubMed
28.
Yu CP et al. Tumor susceptibility and prognosis of breast cancer associated with the G870A polymorphism of CCND1. Breast Cancer Res Treat. 2008;107(1):95–102.PubMedCrossRef
29.
Naidu R, Yip CH, Taib NA. Polymorphisms of HER2 Ile655Val and cyclin D1 (CCND1) G870A are not associated with breast cancer risk but polymorphic allele of HER2 is associated with nodal metastases. Neoplasma. 2008;55(2):87–95.PubMed
30.
Driver KE et al. Association of single-nucleotide polymorphisms in the cell cycle genes with breast cancer in the British population. Carcinogenesis. 2008;29(2):333–41.PubMedCrossRef
31.
Millar EK et al. Cyclin D1b protein expression in breast cancer is independent of cyclin D1a and associated with poor disease outcome. Oncogene. 2009;28(15):1812–20.PubMedPubMedCentralCrossRef
32.
Yaylim-Eraltan I et al. Breast cancer and cyclin D1 gene polymorphism in Turkish women. In Vivo. 2009;23(5):767–72.PubMed
33.
Justenhoven C et al. Polymorphic loci of E2F2, CCND1 and CCND3 are associated with HER2 status of breast tumors. Int J Cancer. 2009;124(9):2077–81.PubMedCrossRef
34.
Haiman CA et al. Screening and association testing of common coding variation in steroid hormone receptor co-activator and co-repressor genes in relation to breast cancer risk: the multiethnic cohort. BMC Cancer. 2009;9:43.PubMedPubMedCentralCrossRef
35.
Canbay E et al. CCND1 and CDKN1B polymorphisms and risk of breast cancer. Anticancer Res. 2010;30(7):3093–8.PubMed
36.
Jelonek K et al. Association between single-nucleotide polymorphisms of selected genes involved in the response to DNA damage and risk of colon, head and neck, and breast cancers in a Polish population. J Appl Genet. 2010;51(3):343–52.PubMedCrossRef
37.
Jeon S et al. Combined genetic effect of CDK7 and ESR1 polymorphisms on breast cancer. Breast Cancer Res Treat. 2010;121(3):737–42.PubMedCrossRef
38.
Absenger, G., et al. (2013). A common and functional gene variant in the vascular endothelial growth factor a predicts clinical outcome in early-stage breast cancer. Mol Carcinog.
39.
Bedewy AM et al. Association of cyclin D1 A870G polymorphism with two malignancies: acute lymphoblastic leukemia and breast cancer. J BUON. 2013;18(1):227–38.PubMed
40.
41.
Simpson JF et al. Amplification of CCND1 and expression of its protein product, cyclin D1, in ductal carcinoma in situ of the breast. Am J Pathol. 1997;151(1):161–8.PubMedPubMedCentral
42.
Gillett CE et al. Cyclin D1 and associated proteins in mammary ductal carcinoma in situ and atypical ductal hyperplasia. J Pathol. 1998;184(4):396–400.PubMedCrossRef
43.
Betticher DC et al. Alternate splicing produces a novel cyclin D1 transcript. Oncogene. 1995;11(5):1005–11.PubMed
44.
Wu J et al. Identification of the cyclin D1b mRNA variant in mouse. Mol Biol Rep. 2009;36(5):953–7.PubMedCrossRef
45.
Lu F, Gladden AB, Diehl JA. An alternatively spliced cyclin D1 isoform, cyclin D1b, is a nuclear oncogene. Cancer Res. 2003;63(21):7056–61.PubMed
46.
Pabalan N et al. Cyclin D1 Pro241Pro (CCND1-G870A) polymorphism is associated with increased cancer risk in human populations: a meta-analysis. Cancer Epidemiol Biomarkers Prev. 2008;17(10):2773–81.PubMedCrossRef
47.
Lu C et al. CCND1 G870A polymorphism contributes to breast cancer susceptibility: a meta-analysis. Breast Cancer Res Treat. 2009;116(3):571–5.PubMedCrossRef
48.
Sergentanis TN, Economopoulos KP. Cyclin D1 G870A polymorphism and breast cancer risk: a meta-analysis comprising 9,911 cases and 11,171 controls. Mol Biol Rep. 2011;38(8):4955–63.PubMedCrossRef
49.
Cui J, Shen L, Wang Y. Specific CCND1 G870A alleles associated with breast cancer susceptibility: a meta-analysis of 5,528 cases and 5,353 controls. Asian Pac J Cancer Prev. 2012;13(10):5023–5.PubMedCrossRef
50.
Yang J et al. Cyclin D1 G870A polymorphism and breast cancer risk: a meta-analysis involving 23,998 subjects. Oncol Res. 2011;19(12):519–25.PubMedCrossRef
Metadata
Title
Genetic association between cyclin D1 polymorphism and breast cancer susceptibility
Authors
XiaoRui Li
XiaoQing Huo
WeiWei Li
QingHui Yang
Ying Wang
XiaoChun Kang
Publication date
01-12-2014
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 12/2014
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-014-2489-5

Other articles of this Issue 12/2014

Tumor Biology 12/2014 Go to the issue

Research Article

The clinical implications of Crk-like adaptor protein expression in papillary thyroid microcarcinoma

Research Article

Elucidation of caveolin 1 both as a tumor suppressor and metastasis promoter in light of epigenetic modulators

Research Article

Glucocorticoid receptor DNA binding factor 1 expression and osteosarcoma prognosis

Research Article

CD109 is a potential target for triple-negative breast cancer

Research Article

Effects of interleukin-18 promoter (C607A and G137C) gene polymorphisms and their association with oral squamous cell carcinoma (OSCC) in northern India

Research Article

HMGB1 promotes cellular proliferation and invasion, suppresses cellular apoptosis in osteosarcoma
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits